A House committee is looking into the FDA's warning letter publication process; Amgen and Roche collaborate on cancer combination drug; study shows online health information fails teenagers
The FTC is suing AbbVie and two other firms in a pay-for-delay case that could have wider implications for pharma
The agency says outlets need to rethink running ads that make false claims.
The FTC approved J&J's bid to buy Swiss device maker Synthes, but, as with European regulators, the green light came with a caveat: J&J must divest its DePuy Orthopaedics Trauma business, as it would otherwise dominate the US wrist fracture market.
The makers of POM Wonderful pomegranate juice are firing back at the Federal Trade Commission with an ad campaign featuring the tagline: "FTC v. POM: You Be the Judge."
Federal regulators gave IMS Health the go-ahead to buy SDI Health, and IMS's parent company must now divest two SDI product lines.
An Abbott iPhone app is drawing attention to the practice of compensating bloggers for app reviews, as some call into question the ethics of pay-for-play online PR.
Pharmaceutical advertisers use an array of tactics to gather information about online health seekers in a way that is unfair and deceptive, consumer advocates have charged in a complaint filed with the Federal Trade Commission (FTC).
A judge magistrate said that federal antitrust officials did not overstep or share confidential information while probing whether Cephalon illegally settled patent disputes with Watson Pharmaceuticals and others, but he disagreed with the way antitrust officials conducted the investigation.
A US magistrate judge ruled that the Federal Trade Commission overstepped its authority when the agency tried to pressure a generic drug company to enter into a business deal with a competitor.
Two senators grilled the chairman of the Federal Trade Commission (FTC) yesterday over allegations made by Watson Pharmaceuticals that the agency used its subpoena power and access to confidential information to force the company into a business deal with a rival generics firm.
The FTC, which opposes reverse-payment patent settlements but has failed to muffle them via the courts or healthcare reform legislation, is now trying some new tactics: harassment, use of privileged information and attempting to force a pharma company to partner with another firm against its will.
The nomination of former Vermont assistant attorney general Julie Brill to serve on the Federal Trade Commission would, if confirmed, be the latest of several appointments to give the healthcare industry pause.
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- As immuno-oncology therapies evolve, so will the marketing
- GSK Consumer Healthcare to prioritize digital after agency review
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Tuesday, July 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- Sponsored Podcast: No Patient Left Behind: Connecting Rare Disease Patients to Orphan Drug Manufacturers
- W2O names Gillespie chief strategy officer of medtech practice
- Five things for pharma marketers to know: Wednesday, July 27, 2016
- DigitasLBi's Carlos Ricque on Why Simple Ads Are the Hardest to Make
- Healthcare marketers: Don't forget about the baby boomers